The US National Cancer Institute Expands Contract with GENEART by USD 0.8M
News Jul 01, 2008
The NIH are therefore increasing the order volume for the production of genes for the "Mammalian Gene Collection (MGC)" to a total of USD 2.7M in 2008.
More than 3,500 genes with an order volume of approximately USD 3.5M were produced by GENEART last year as part of the basic contract.
The National Cancer Institute uses the genes synthesized by GENEART to supplement the Mammalian Gene Collection - a comprehensive collection of genes from mice, rats, and humans, both for basic research and for applied medical research.
The genes that have been produced so far are composed of complex repeat motifs, they are quite large and for most part are rare transcripts. In order to produce the requested highly complex genes efficiently in high throughput, GENEART further advanced its synthesis processes and established new production techniques last year.
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.
Researchers published today a detailed description of the complete genome of bread wheat, the world's most widely-cultivated crop. This work will pave the way for the production of wheat varieties better adapted to climate challenges, with higher yields, enhanced nutritional quality and improved sustainability.